Prognostic Value of Pololike Kinase Expression in Melanomas

Strebhardt, Klaus; Kneisel, Lucas; Linhart, Carola; Bernd, August; Kaufmann, Roland

doi:10.1001/jama.283.4.479

Cited by 75 publications

(59 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, high levels of Plk1 protein expression have been detected in breast (Yuan et al, 1997;Wolf et al, 2000), ovarian (Takai et al, 2001;Weichert et al, 2004), head and neck squamous cell carcinoma (Knecht et al, 2000), and melanoma tumor specimens using an immunohistochemical approach. In some of the studies described above, a statistically significant correlation was found between high Plk1 expression and low patient survival, suggesting that Plk1 may have utility as a negative prognostic indicator for some tumor types Knecht et al, 1999;Tokumitsu et al, 1999;Knecht et al, 2000;Strebhardt et al, 2000;Weichert et al, 2004).…”

Section: Normal Adult Tissues and Tumor Specimensmentioning

confidence: 98%

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

Winkles

Alberts²

2005

Oncogene

139

123

View full text Add to dashboard Cite

Section: Normal Adult Tissues and Tumor Specimensmentioning

confidence: 98%

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

Winkles

Alberts²

2005

Oncogene

139

123

View full text Add to dashboard Cite

“…Results were independently assessed in a semiquantitative fashion by the two investigators. Prognostic evaluations were based on the mean PLK index similar to the previous studies (11,12).…”

Section: Patients and Human Samplesmentioning

confidence: 99%

Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Kawata

Ashihara

Kimura

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Liver metastasis is one of the most important prognostic factors in lung cancer patients. However, current therapies are not sufficient. RNA interference provides us a powerful and promising approach for treating human diseases including cancers. Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer. PLK-1 was overexpressed in cell lines and in cancerous tissues from lung cancer patients. PLK-1 siRNA treatment inhibited growth and induced apoptosis in a concentration-dependent manner. To verify in vivo efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted luciferase-labeled A549 LUC cells by detecting reduced bioluminescence after an i.v. injection of luciferase GL3 siRNA/atelocollagen. PLK-1 siRNA/ atelocollagen was also successfully transfected into cells and inhibited the progression of metastases. This study shows the efficacy of i.v. administration of PLK-1 siRNA/ atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer. [Mol Cancer Ther 2008;7(9):2904 -12]

show abstract

“…Plk1 overexpression is positively correlated with aggressiveness in a variety of human tumors, including melanomas, gliomas, nonsmall-cell lung, head and neck, esophageal, gastric, breast, ovarian, endometrial, colorectal and thyroid cancers (Wolf et al, 1997;Knecht et al, 1999Knecht et al, , 2000Strebhardt et al, 2000;Eckerdt et al, 2005;Takai et al, 2005). Patients with a moderate Plk1 expression level usually survive longer than those with a high Plk1 level.…”

Section: Introductionmentioning

confidence: 99%

Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint

Lei

Erikson

2008

Oncogene

View full text Add to dashboard Cite

We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the long term, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.

show abstract

Prognostic Value of Pololike Kinase Expression in Melanomas

Cited by 75 publications

References 3 publications

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint

Contact Info

Product

Resources

About